Update on allergy immunotherapy: American Academy of Allergy, Asthma & Immunology/European Academy of Allergy and Clinical Immunology/PRACTALL consensus report - 29/04/13
, Moises A. Calderon, MD, PhD b, Thomas Casale, MD c, Linda Cox, MD d, Pascal Demoly, MD, PhD e, Marek Jutel, MD f, Harold Nelson, MD g, Cezmi A. Akdis, MD h
Corresponding author: A. Wesley Burks, MD, University of North Carolina, Department of Pediatrics, 260 MacNider Building, Campus Box 7220, Chapel Hill, NC 27599-7220.Abstract |
Allergy immunotherapy (AIT) is an effective treatment for allergic asthma and rhinitis, as well as venom-induced anaphylaxis. In addition to reducing symptoms, AIT can change the course of allergic disease and induce allergen-specific immune tolerance. In current clinical practice immunotherapy is delivered either subcutaneously or sublingually; some allergens, such as grass pollen, can be delivered through either route, whereas others, such as venoms, are only delivered subcutaneously. Both subcutaneous and sublingual immunotherapy appear to have a duration of efficacy of up to 12 years, and both can prevent the development of asthma and new allergen sensitivities. In spite of the advances with AIT, safer and more effective AIT strategies are needed, especially for patients with asthma, atopic dermatitis, or food allergy. Novel approaches to improve AIT include use of adjuvants or recombinant allergens and alternate routes of administration. As part of the PRACTALL initiatives, the European Academy of Allergy and Clinical Immunology and the American Academy of Allergy, Asthma & Immunology nominated an expert team to develop a comprehensive consensus report on the mechanisms of AIT and its use in clinical practice, as well as unmet needs and ongoing developments in AIT. This resulting report is endorsed by both academies.
Le texte complet de cet article est disponible en PDF.Key words : Allergen immunotherapy, atopic disease, immune tolerance
Abbreviations used : AIT, OIT, SCIT, SLIT, TLR, Treg
Plan
| Disclosure of potential conflict of interest: A. W. Burks is a board member of the American Academy of Allergy, Asthma & Immunology (AAAAI); the Hypersensitivity, Autoimmunity, and Immune-mediated Diseases Study Section for the National Institutes of Health (NIH); the Food and Drug Administration Food Advisory Committee; the Food Allergy & Anaphylaxis Network Research Advisory Board; and the Merck US Allergy Immunotherapy Allergist Advisory Board; has had consultant arrangements with ActoGeniX, Curalogic, Dow Agrosciences, McNeill Nutritionals, Merck, Novartis Pharma AG, Sanofi-Aventis US, Schering-Plough, and Unilever; is employed by the University of North Carolina Children’s Hospital; was previously employed by Duke University; has received research support from the NIH and the Wallace Research Foundation; has received payment for lectures from Abbott Laboratories and Mylan Specialty; has patents related to peanut allergy planned or pending; has received payment for development of educational presentations from Current Views 2012; and is a minority stockholder in Allertein. T. Casale has received grants from Novartis, Stallergenes, Genentech, and Merck; has consultant arrangements with Novartis, Stallergenes, Genentech, and ALK-Abelló; and is the executive vice president of the AAAAI. L. Cox has consultant arrangements with Stallergenes and the US Food and Drug Administration Allergenic Products Advisory Committee; has received travel support from the AAAAI; has received fees for participating in review activities from Carcissa and Novartis; has received payment for writing or reviewing the manuscript from the Blue Cross Blue Shield Technology Evaluation Center; is a board member for the American Board of Allergy and Immunology; has provided expert testimony in cases related to chronic ciguatera; and has received payment for lectures from the Southeastern Allergy Asthma Immunology Association and the Virginia Allergy Asthma and Immunology Society. P. Demoly has received consulting fees or honoraria from ALK-Abelló, Stallergenes, Circassia, and Allergopharma and has consultant arrangements with Merck, AstraZeneca, Menarini, Chiesi, and GlaxoSmithKline. M. Jutel has consultant arrangements with Anergis and Allergopharma and has received payment for lectures from Allergopharma, Stallergenes, and GlaxoSmithKline. H. Nelson has consultant arrangements with Merck and Circassia and has received grants from Circassia. C. A. Akdis has received grants from Novartis, the European Commission, the Swiss National Science Foundation, the Global Allergy and Asthma European Network, and the Christine Kühne–Center for Allergy Research and Education; has consulted for Actellion, Aventis, Stallergenes, and Allergopharma; is president of the European Academy of Allergy and Clinical Immunology; is a fellow and interest group member of the AAAAI; is a former committee member of GA2LEN, and is director of the Christine Kühne–Center for Allergy Research and Education. M. Calderon declares that he has no relevant conflicts of interest. |
Vol 131 - N° 5
P. 1288 - mai 2013 Retour au numéro
Article précédent
- Mechanisms underlying helper T-cell plasticity: Implications for immune-mediated disease
- Kiyoshi Hirahara, Amanda Poholek, Golnaz Vahedi, Arian Laurence, Yuka Kanno, Joshua D. Milner, John J. O’Shea
- Partial defects of T-cell development associated with poor T-cell function
- Luigi D. Notarangelo
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?